Drug re-positioning (DR) is a strategy to discover the new pharmacological effects of drugs sufficiently approved in terms of safety and pharmacokinetics in humans and to develop therapeutic agents for other diseases.
The following are major advantages of DR in pharmaceutical development:
Using our own library targeted for compounds from drugs approved in Japan, we have performed various screenings to advance DR (including drugs for COPD, dry eye or functional dyspepsia). We also offer our library to partners for free and work together for DR promotion.
To enhance the pharmacological effect of an approved drug from screening or obtain a substance patent, we have created a new substance by synthesizing derivatives with the approved drug as a lead compound (for example, LT-3001, LT-3002).
Many pharmaceutical companies have compounds discontinued from clinical development (shelved drugs) because of the lack of a pharmacological effect in spite of confirmation of clinical safety. Successful discovery of a pharmacological effect with DR development of a therapeutic agent for other diseases will bring great advantages to these companies. Our business includes DR of these compounds commissioned by major companies.
By DR strategy, we can develop safe drugs,
rapidly, economically and certainly.